← Back to Search


rTMS for Obsessive-Compulsive Disorder

Led By Nolan Williams, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up pre-treatment up to 1-month post-treatment
Awards & highlights

Study Summary

This trial will study how brain activity affects OCD, and test new treatments to see if they help.

Who is the study for?
This trial is for adults aged 18-80 with Obsessive-Compulsive Disorder (OCD) who have a moderate severity score and have not responded to or refused standard treatments. Participants must be able to consent, may be on stable SRI medication, and complete MRI safety screening. Exclusions include primary psychiatric diagnoses other than OCD, severe personality disorders, active suicidality, metal in the body, unstable physical conditions, drug abuse, certain neurological disorders or history of seizures.Check my eligibility
What is being tested?
The study aims to identify brain-based subtypes of OCD and assess how well two different rTMS targets—the medial prefrontal cortex (MPFC) and the right prefrontal cortex (rPFC)—work in treating symptoms. It involves non-invasive magnetic stimulation of specific brain areas.See study design
What are the potential side effects?
rTMS is generally safe but can cause discomfort at the stimulation site, headache, lightheadedness or tingling. Rarely it might induce seizures or hearing loss if ear protection isn't used.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-treatment up to 1-month post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-treatment up to 1-month post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
resting-state functional connectivity (rsFC) of frontostriatal networks
Secondary outcome measures
OCD symptoms

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Medial Prefrontal Cortex (MPFC)Experimental Treatment1 Intervention
Intermittent theta-burst stimulation (iTBS) of MPFC at up to 100% resting motor threshold (RMT), with lower extremity RMT established for the MPFC target.
Group II: Right Prefrontal Cortex (rPFC)Active Control1 Intervention
Continuous theta-burst stimulation (cTBS) of rPFC at up to 110% of RMT, with upper extremity RMT established for the rPFC target.
First Studied
Drug Approval Stage
How many patients have taken this drug
Repetitive Transcranial Magnetic Stimulation
Completed Phase 3

Find a Location

Who is running the clinical trial?

Foundation for OCD ResearchUNKNOWN
1 Previous Clinical Trials
120 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
120 Patients Enrolled for Obsessive-Compulsive Disorder
Cornell UniversityOTHER
167 Previous Clinical Trials
14,089,620 Total Patients Enrolled
Stanford UniversityLead Sponsor
2,410 Previous Clinical Trials
17,343,031 Total Patients Enrolled
15 Trials studying Obsessive-Compulsive Disorder
1,043 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Repetitive Transcranial Magnetic Stimulation (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05829681 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Medial Prefrontal Cortex (MPFC), Right Prefrontal Cortex (rPFC)
Obsessive-Compulsive Disorder Clinical Trial 2023: Repetitive Transcranial Magnetic Stimulation Highlights & Side Effects. Trial Name: NCT05829681 — N/A
Repetitive Transcranial Magnetic Stimulation (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05829681 — N/A
~192 spots leftby Mar 2027